AAV-loadable hypercompact ABEs developed by GenKOre

GenKOre (homepage: www.genkore.com) is a biotech spun off from the Korea Research Institute of Bioscience and Biotechnology (KRIBB), which is a government-invested research institute in Korea. It has platform business through highly efficient genome editing platform. They develop AAV/non-viral-based gene therapy and new plant varieties using its own genome editing technology. Previously, GenKOre developed a hypercompact CRISPR system with AAV delivery compatibility, coined TaRGET (Tiny nuclease/augment RNA-based Genome Editing Technology), which was published in Nature Biotechnology in 2021.

South Korea, 02/08/2022 (informazione.news - comunicati stampa - scienza e tecnologia)

GenKOre (homepage: www.genkore.com) is a biotech spun off from the Korea Research Institute of Bioscience and Biotechnology (KRIBB), which is a government-invested research institute in Korea. It has platform business through highly efficient genome editing platform. They develop AAV/non-viral-based gene therapy and new plant varieties using its own genome editing technology. Previously, GenKOre developed a hypercompact CRISPR system with AAV delivery compatibility, coined TaRGET (Tiny nuclease/augment RNA-based Genome Editing Technology), which was published in Nature Biotechnology in 2021.

This new base-editing technology is expected to provide various treatment options for genetic diseases through AAV delivery. Alternatively, the ABE system is expected to harness the development of gene-editing therapy targeting immune cells and hematopoietic stem cells.

The related article published on Nature Chemical Biology can be checked at: https://www.nature.com/articles/s41589-022-01077-5.

GenKOre website: www.genkore.com

Photo - https://mma.prnewswire.com/media/1870659/Gene_editing.jpg